Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

CESNE, A. L ; JUDSON, I ; BLAY, J.-Y ; MAKI, R ; GROSSO, F ; SCHUETZE, S ; MEHREN, M. V ; CHAWLA, S. P ; DEMETRI, G. D ; NIETO, A ; TANOVIC, A

British journal of cancer, 2013-10, Vol.109 (7), p.1717-1724 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível